MEDICUD, an innovative Italian medical device startup specializing in wound healing solutions, has successfully secured €500,000 in funding to accelerate the clinical development of its groundbreaking product, DRYUM. This incisional negative pressure wound therapy system is revolutionizing post-operative care by seamlessly combining established medical standards with remarkable patient comfort. Unlike traditional approaches, DRYUM stands out as the only ultraportable mechanical system that reliably maintains constant negative pressure throughout the entire course of treatment, empowering patients with the freedom to heal on the go. With this funding, MEDICUD aims to enhance its ongoing clinical trials and establish DRYUM as the new gold standard in incisional surgery. Surgical site infections and dehiscence are serious complications that affect countless patients, and by integrating cost-effective and environmentally friendly solutions—such as bio-sourced polymers and the absence of embedded electronics—MEDICUD is taking significant strides in improving patient outcomes while also reducing ecological impact. The funds will not only bolster the clinical phase but also assist in expanding MEDICUD's research capabilities and outreach initiatives to healthcare professionals worldwide. As DRYUM progresses through human trials, MEDICUD is poised to make a significant dent in the healthcare landscape, driving better recovery experiences and outcomes for patients globally. This funding marks an exciting milestone for MEDICUD, propelling the company forward as they gear up to redefine the standards of care in wound management.





